This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
 Support & Resources
Blood. Essential to life, and to our work.

More than 1 million people worldwide were diagnosed with a blood cancer in 2020, representing about 7% of all cancer diagnoses globally.1

Pfizer Haematology is motivated by the belief that science can win as we make progress in our mission. With the resources of our global enterprise, we are dedicated to continuing our efforts in bold innovation, patient-centricity, and robust support services.

Continue learning about Pfizer's commitment to haematology below.

See how driving innovation is in our blood.

Blood cancers remain an area of many unmet needs and we are determined to find breakthroughs in this important therapeutic space.

 Watch video LoadingOur mission for people living with LeukaemiaAcute Lymphoblastic  We continue to provide support to the ALL community.

Acute lymphoblastic leukaemia (ALL) is an aggressive and rapidly progressing cancer of blood and bone marrow cells, which progresses quickly if left untreated. Additionally, patients may relapse or be refractory to initial treatment.2-5

ALL is another therapeutic space that Pfizer is proud to support patients in as they continue their difficult journey.

Chronic Myelogenous  Pfizer's reach extends to those dealing with CML.

Chronic myelogenous leukaemia (CML) is a slow-growing cancer in which too many myeloblasts are found in the blood and bone marrow. As the number of myeloblasts increases, CML may worsen over time.6

Providing aid to those with CML is our honor and privilege.

References:Worldwide cancer data. World Cancer Research Fund International. Accessed July 2023. https://www.wcrf.org/cancertrends/worldwide-cancer-data/Adult acute lymphoblastic leukaemia treatment (PDQ®)–health professional version. National Cancer Institute . Accessed July 2023. https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq#_14_tocDias A, Kenderian SJ, Westin GF, Litzow MR. Novel therapeutic strategies in acute lymphoblastic leukaemia. Curr Hematol Malig Rep . 2016;11:253-264. doi:10.1007/s11899-016-0326-1Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukaemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13:70. doi:10.1186/s13045-020-00905-2Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukaemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95:589-596. doi:10.3324/haematol.2009.014274Chronic myelogenous leukaemia treatment (PDQ®)–patient version. National Cancer Institute. Accessed October 2023. https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq
PP-INO-IRL-0125. Date of preparation February 2024

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024